Type specific LR-HPV infection.

<p>(A) Prevalence at enrolment. (B) Incidence over 16 months. (C) Persistence over 16 months. *Significantly different between the two countries (i.e. p-value <0.05). **Persistence as a proportion of those positive for that specific type at enrolment.</p

Effect of HIV-related factors and LR-HPV on AGW prevalence at enrolment among 572 WLHIV in BF and 613 in SA.

<p>Effect of HIV-related factors and LR-HPV on AGW prevalence at enrolment among 572 WLHIV in BF and 613 in SA.</p

Associations between prevalent LR-HPV^a and HIV-related factors among 570 WLHIV in BF and 613 in SA.

<p>Associations between prevalent LR-HPV<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0196018#t002fn001" target="_blank">^a</a> and HIV-related factors among 570 WLHIV in BF and 613 in SA.</p

Effect of HIV-related factors and LR-HPV infection on incident AGW among 468 WLHIV in BF and 524 in SA.

<p>Effect of HIV-related factors and LR-HPV infection on incident AGW among 468 WLHIV in BF and 524 in SA.</p

Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa - Fig 2

<p>(A) Association of HR-HPV prevalence with prevalent CIN2 and CIN3+ among 546 women living with HIV in Burkina Faso. (B) Association of HR-HPV prevalence with prevalent CIN2 and CIN3+ among 573 women living with HIV in South Africa.</p

Risk of incident CIN2+ according to HR-HPV infection status over 16 months among 405 Women Living with HIV (WLHIV) without CIN2+ at enrolment in Burkina Faso and 375 WLHIV in South Africa.

<p>Risk of incident CIN2+ according to HR-HPV infection status over 16 months among 405 Women Living with HIV (WLHIV) without CIN2+ at enrolment in Burkina Faso and 375 WLHIV in South Africa.</p